The European Commission Has Granted Marketing Authorization In Europe For Valneva's Single-dose Vaccine, Ixchiq, For Individuals 18 Years Of Age And Older. The Company Expects To Deliver The First Doses In Europe In Q4 Of 2024

7/1/24 6:40:29 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $VALN alert in real time by email

Get the next $VALN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VALN

Date	Price Target	Rating	Analyst
8/3/2022	$34.00	Buy	H.C. Wainwright

More analyst ratings

$VALN
Financials

Live finance-specific insights

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D budget for partnered Lyme disease program were completed in the second quarter of the year Full-year 2024 Financial Guidance Narrowed Expected total product sales according to guidan
11/7/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasingNet Profit of €34.0 million, including proceeds from PRV sale Operating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023 Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed its cost contributions to the agreed R&D budget for its partnered Lyme disease program in the second quarterSignificantly extended cash runway with update of debt financing agreement1 Full-year 2024 Financial
8/13/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance Cash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV)1. Significantly extended cash runway with recent update of debt financing agreement2Substantially lower cash burn expected in 2024 as Valneva expects to complete its cost contributions for the Lyme disease Phase 3 study in the second quarter Net Profit of €58.9 million, reflecting PRV sale 2024 financial guidance confirmed Expected tot
5/7/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director to its Board. Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. Guyot-Caparros has a proven track record in finance and business
6/26/24 11:45:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Saint-Herblain (France), May 21, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva's pre-clinical and translational R&D activities in support of the Company's strategic ambition to provide first-, best- or only-in-class vaccine solutions. Dr. Schuitemaker brings more than two decades of experience in vacc
5/21/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board
Saint-Herblain (France), June 21, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2022 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, as well as the appointment of a new Supervisory Board member and the reappointment of two of them. Dr Kathrin U Jansen, Ph.D., a German national with over 30 years of vaccine R&D experience, was appointed to Valneva's Supervisory
6/21/23 12:15:00 PM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech1. In the CHIM study S4V03 (Identifier: NCT06615375), S4V2 will be tested for safety and preliminary efficacy in approximate
11/13/24 11:45:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Saint-Herblain (France), November 12, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated "fireside chat" presentations to discuss the Company's key value drivers and upcoming catalysts, which include multiple clinical data events in 2025, most notably key Phase 3 conclusions for VLA15, the Company's Lyme disease vaccine candidate, which is partnered with Pfizer. If successful, Pfiz
11/12/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates
Nine-Month Key Financial Highlights Total revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV)1 sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023 Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement2Lower cash burn expected in the second half of 2024 as cost contributions to the agreed R&D budget for partnered Lyme disease program were completed in the second quarter of the year Full-year 2024 Financial Guidance Narrowed Expected total product sales according to guidan
11/7/24 1:00:00 AM ET
$VALN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

The European Commission Has Granted Marketing Authorization In Europe For Valneva's Single-dose Vaccine, Ixchiq, For Individuals 18 Years Of Age And Older. The Company Expects To Deliver The First Doses In Europe In Q4 Of 2024

Chat with this insight

Recent Analyst Ratings for
$VALN

$VALN
Financials

Live finance-specific insights

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

$VALN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Valneva SE with a new price target

$VALN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$VALN
Leadership Updates

Live Leadership Updates

$VALN
SEC Filings

$VALN
Market Insights

Live Market Insights

$VALN
Press Releases

Fastest customizable press release news feed in the world

Amendment: SEC Form SC 13D/A filed by Valneva SE

SEC Form SC 13G/A filed by Valneva SE (Amendment)

SEC Form SC 13D/A filed by Valneva SE (Amendment)

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board

SEC Form 6-K filed by Valneva SE

SEC Form 6-K filed by Valneva SE

SEC Form 6-K filed by Valneva SE

What Analysts Are Saying About Valneva Stock

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target

CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

The European Commission Has Granted Marketing Authorization In Europe For Valneva's Single-dose Vaccine, Ixchiq, For Individuals 18 Years Of Age And Older. The Company Expects To Deliver The First Doses In Europe In Q4 Of 2024

Chat with this insight

Recent Analyst Ratings for $VALN

$VALN Financials

Live finance-specific insights

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

$VALN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Valneva SE with a new price target

$VALN Large Ownership Changes

This live feed shows all institutional transactions in real time.

$VALN Leadership Updates

Live Leadership Updates

$VALN SEC Filings

$VALN Market Insights

Live Market Insights

$VALN Press Releases

Fastest customizable press release news feed in the world

Amendment: SEC Form SC 13D/A filed by Valneva SE

SEC Form SC 13G/A filed by Valneva SE (Amendment)

SEC Form SC 13D/A filed by Valneva SE (Amendment)

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer's Former Vaccine R&D Head to its Supervisory Board

SEC Form 6-K filed by Valneva SE

SEC Form 6-K filed by Valneva SE

SEC Form 6-K filed by Valneva SE

What Analysts Are Saying About Valneva Stock

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target

CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Recent Analyst Ratings for
$VALN

$VALN
Financials

$VALN
Analyst Ratings

$VALN
Large Ownership Changes

$VALN
Leadership Updates

$VALN
SEC Filings

$VALN
Market Insights

$VALN
Press Releases